Brilinta, Growing Diabetes Line-Up Spotlighted By New AstraZeneca CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Growth potential for AstraZeneca's new cardiovascular drug Brilinta and its diabetes franchise were highlighted by the group’s new CEO Pacal Soriot during a third-quarter analysts' call but further details of his strategic thinking must wait at least until the end of January 2013.
You may also be interested in...
AstraZeneca Building Japan Presence Ahead Of Crestor Loss
Phase III results are expected soon for a Japanese study of Brilinta, and the company hopes to have a fresh start for a new, but slow-growing product.
Emerging Markets Earnings Roundup: AstraZeneca And Novartis (Part 2)
Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.